Study of pirtobrutinib, venetoclax, and rituximab for Waldenström's macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Waldenström's macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL) that is not caused by IgM antibodies (non-IgM LPL is not allowed).
- You have not had any prior treatment for this disease.
- You have at least one enlarged lymph node (≥1.5 cm) or high IgM levels (>0.5 g/dL).
- You have symptoms or blood test abnormalities (like anemia, low platelets, nerve pain, high blood viscosity, kidney problems, or large tumor burden) that require treatment.
- You are able to swallow pills and have adequate organ function (kidney, liver, and blood counts within limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.